0001193125-13-466162.txt : 20131209 0001193125-13-466162.hdr.sgml : 20131209 20131209113622 ACCESSION NUMBER: 0001193125-13-466162 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20131209 FILED AS OF DATE: 20131209 DATE AS OF CHANGE: 20131209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Theratechnologies Inc. CENTRAL INDEX KEY: 0001512717 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35203 FILM NUMBER: 131264808 BUSINESS ADDRESS: STREET 1: 2310 ALFRED-NOBEL BLVD. CITY: MONTREAL STATE: A8 ZIP: H4S 2B4 BUSINESS PHONE: 514-336-7800 MAIL ADDRESS: STREET 1: 2310 ALFRED-NOBEL BLVD. CITY: MONTREAL STATE: A8 ZIP: H4S 2B4 6-K 1 d639925d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

December 9, 2013

Commission File Number 001-35203

 

 

THERATECHNOLOGIES INC.

(Translation of registrant’s name into English)

 

 

2310 Alfred-Nobel Boulevard

Montréal, Québec, Canada

H4S 2B4

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  x    Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨    No  x

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨    No   x

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨    No   x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-__________.

 

 

 

THERATECHNOLOGIES INC.

 

Exhibit

   

Description

99.1    Material Change Report dated December 9, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

THERATECHNOLOGIES INC.
By:   /s/ Jocelyn Lafond
Name:   Jocelyn Lafond
Title:   Vice President, Legal Affairs

Date: December 9, 2013

EX-99.1 2 d639925dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

MATERIAL CHANGE REPORT

Regulation 51-102 Respecting Continuous Disclosure Obligations

Form 51-102F3

ITEM 1 - NAME AND ADDRESS OF COMPANY

THERATECHNOLOGIES INC.

2310 Alfred-Nobel Boulevard

Montreal, Québec

Canada H4S 2B4

ITEM 2 - DATE OF MATERIAL CHANGE

December 3, 2013

ITEM 3 - NEWS RELEASE

A news release describing this material change was issued on December 3, 2013 on “Marketwire”. A copy of the news release is available on the SEDAR website at www.sedar.com.

ITEM 4 - SUMMARY OF MATERIAL CHANGE

On December 3, 2013, Theratechnologies Inc. (the “Corporation”) announced that it resumed shipment of EGRIFTATM (tesamorelin for injection) to EMD Serono, Inc. in the United States.

The Corporation also announced that it was notified by Jubilant HollisterStier (“Jubilant”), its third-party contract manufacturer of tesamorelin, that the strike initiated by Jubilant’s employees at its manufacturing site located in Montreal, Canada, was over.

ITEM 5 - FULL DESCRIPTION OF MATERIAL CHANGE

5.1 Full description of material change

On December 3, 2013, the Corporation announced that it resumed shipment of EGRIFTATM (tesamorelin for injection) to EMD Serono, Inc. in the United States.

The Corporation also announced that it was notified by Jubilant, its third-party contract manufacturer of tesamorelin, that the strike initiated by Jubilant’s employees at its manufacturing site located in Montreal, Canada, was over.

5.2 Disclosure for restructuring transactions

Not applicable.

 

- 2 -

 

ITEM 6 - RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not applicable.

ITEM 7 - OMITTED INFORMATION

Not applicable.

ITEM 8 - EXECUTIVE OFFICER

For further information, contact Jocelyn Lafond, Vice President, Legal Affairs, and Corporate Secretary of the Corporation at (514) 336-4804, ext. 288.

ITEM 9 - DATE OF REPORT

December 9, 2013.